chest pain; shortness of breath/difficulty breathing; heart skipping beats; blockage; fever; vomiting; chills; fatigue; A fast heart rate; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (shortness of breath/difficulty breathing), HEART RATE INCREASED (a fast heart rate), CHEST PAIN (chest pain), EXTRASYSTOLES (heart skipping beats) and ATRIOVENTRICULAR BLOCK (blockage) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 018B21A and 036A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-Oct-2021, the patient experienced EXTRASYSTOLES (heart skipping beats) and ATRIOVENTRICULAR BLOCK (blockage). On an unknown date, the patient experienced DYSPNOEA (shortness of breath/difficulty breathing), HEART RATE INCREASED (a fast heart rate), CHEST PAIN (chest pain), PYREXIA (fever), VOMITING (vomiting), CHILLS (chills) and FATIGUE (fatigue). At the time of the report, DYSPNOEA (shortness of breath/difficulty breathing) and CHEST PAIN (chest pain) had not resolved, HEART RATE INCREASED (a fast heart rate), PYREXIA (fever), VOMITING (vomiting), CHILLS (chills) and FATIGUE (fatigue) had resolved and EXTRASYSTOLES (heart skipping beats) and ATRIOVENTRICULAR BLOCK (blockage) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 19-Oct-2021, Electrocardiogram: abnormal (abnormal) abnormal.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported. This case concerns a 36-year-old female patient with no relevant medical history who experienced non-serious unexpected events of special interest extra systoles, atrioventricular block, and chest pain. The event of chest pain occurred after the first dose of COVID19 MODERNA whereas the remaining events were diagnosed after the second dose of COVID19 MODERNA. Reportedly, immediately after the first dose, the patient started experiencing chest pain along with other events. The chest pain was off and on ever since the first dose but it had became constant in the last couple of months.  The patient was later diagnosed by her PCP with heart skipping beats and blockage after an abnormal EKG.  The patient was supposed to be seeing a cardiologist for an additional testing. Rechallenge was not applicable for all of the events. since chest pain was ongoing ever since the first dose, whereas the remaining events occurred after the second dose so no rechallenge was done and thus, recurrence was not applicable. The benefit-risk relationship of drug is not affected by this report   This case was linked to MOD-2021-359960 (Patient Link).; Sender's Comments: This case concerns a 36-year-old female patient with no relevant medical history who experienced non-serious unexpected events of special interest extra systoles, atrioventricular block, and chest pain. The event of chest pain occurred after the first dose of COVID19 MODERNA whereas the remaining events were diagnosed after the second dose of COVID19 MODERNA. Reportedly, immediately after the first dose, the patient started experiencing chest pain along with other events. The chest pain was off and on ever since the first dose but it had became constant in the last couple of months.  The patient was later diagnosed by her PCP with heart skipping beats and blockage after an abnormal EKG.  The patient was supposed to be seeing a cardiologist for an additional testing. Rechallenge was not applicable for all of the events. since chest pain was ongoing ever since the first dose, whereas the remaining events occurred after the second dose so no rechallenge was done and thus, recurrence was not applicable. The benefit-risk relationship of drug is not affected by this report